Cited by 201Antiplatelet Therapy and Cardiovascular DiseasesCardiac Imaging and DiagnosticsHealth Promotion and Cardiovascular Prevention

Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis)

Open access
Cainzos-Achirica, Miguel, Miedema, Michael D., McEvoy, John W., Al Rifai, Mahmoud, Greenland, Philip, Dardari, Zeina, Budoff, Matthew, Blumenthal, Roger S. +7 more·2020·Circulation

Abstract

Background: Recent American College of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but not at high risk of bleeding. However, it remains unclear how these patients are best identified. The present study aimed to assess the value of coronary artery calcium (CAC) for guiding aspirin allocation for primary prevention by using 2019 aspirin meta-analysis data on cardiovascular disease relative risk reduction and bleeding risk. Methods: The study included 6470 participants from the MESA Study (Multi-Ethnic Study of Atherosclerosis). ASCVD risk was estimated using the pooled cohort equations, and 3 strata were defined: <5%, 5% to 20%, and >20%. All participants underwent CAC scoring at baseline, and CAC scores were stratified as =0, 1 to 99, ≥100, and ≥400. A 12% relative risk reduction in cardiovascular disease events was used for the 5-year number needed to treat (NNT 5 ) calculations, and a 42% relative risk increase in major bleeding events was used for the 5-year number needed to harm (NNH 5 ) estimations. Results: Only 5% of MESA participants would qualify for aspirin consideration for primary prevention according to the American College of Cardiology/American Heart Association guidelines and using >20% estimated ASCVD risk to define higher risk. Benefit/harm calculations were restricted to aspirin-naive participants <70 years of age not at high risk of bleeding (n=3540). The overall NNT 5 with aspirin to prevent 1 cardiovascular disease event was 476 and the NNH 5 was 355. The NNT 5 was also greater than or similar to the NNH 5 among estimated ASCVD risk strata. Conversely, CAC≥100 and CAC≥400 identified subgroups in which NNT 5 was lower than NNH 5 . This was true both overall (for CAC≥100, NNT 5 =140 versus NNH 5 =518) and within ASCVD risk strata. Also, CAC=0 identified subgroups in which the NNT 5 was much higher than the NNH 5 (overall, NNT 5 =1190 versus NNH 5 =567). Conclusions: CAC may be superior to the pooled cohort equations to inform the allocation of aspirin in primary prevention. Implementation of current 2019 American College of Cardiology/American Heart Association guideline recommendations together with the use of CAC for further risk assessment may result in a more personalized, safer allocation of aspirin in primary prevention. Confirmation of these findings in experimental settings is needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.119.045010

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Large, observational, prospective data suggest coronary artery calcium as a non-invasive biomarker to identify asymptomatic patients at the highest risk of ASCVD or revascularization, with or without diabetes, who may largely benefit from acetylsalicylic acid.

    “Large, observational, prospective data suggest CAC as a non-invasive biomarker to identify asymptomatic patients at the highest risk of ASCVD or revascularization, with or without diabetes, who may largely benefit from ASA.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cainzos-Achirica, M., Miedema, M. D., McEvoy, J. W., Al Rifai, M., Greenland, P., Dardari, Z., Budoff, M., Blumenthal, R. S., Yeboah, J., Duprez, D. A., Mortensen, M. B., Dzaye, O., Hong, J., Nasir, K., & Blaha, M. J.
Affiliations
  • Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, The Johns Hopkins University, Baltimore, MD (M.C.-A., J.W.M., Z.D., R.S.B., O.D., K.N., M.J.B.).
  • Minneapolis Heart Institute Foundation (US)
  • Johns Hopkins University (US)
  • Baylor College of Medicine, Houston, TX (M.A.R.).
  • Northwestern University (US)
  • University of California, Los Angeles (US)
  • Atrium Health Wake Forest Baptist (US)
  • University of Minnesota (US)
  • Aarhus University Hospital (DK)
Venue
Circulation
Published
2020-05-12
Volume
141
Issue
19
Pages
1541-1553
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3014628403
Cited by
201
References
32
Citations by year
2026: 25 · 2025: 33 · 2024: 32 · 2023: 32 · 2022: 33 · 2021: 32 · 2020: 14
FWCI
17.16
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (n01hc95164-17-0-1, UL1TR001420, n01hc95165-34-0-1, n01hc95161-24-0-1, n01hc095169-003, n01hc95166-21-0-1, n01hc95162-31-0-1, n01hc95168-27-0-1, n01hc95160-18-0-1, n01hc095167-000, UL1TR001079, n01hc95159-40-0-1, UL1TR003098, UL1TR000040, UL1TR001881)
  • National Heart, Lung, and Blood Institute (N01 HC-95159, N01-HC095169, N01-HC-095165, UL1-TR-, N01-HC-095159, N01 HC095168, N01-HC-095162, N01-HC-095161, HHSN268201500003C, HHSN26820150 0003I, N01 HC095167, N01-HC-095160, N01 HC095166, N01 HC095164, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, N01 HC95169)
  • National Center for Advancing Translational Sciences (UL1-TR-000040, UL1-TR-001079, UL1-TR, N01-HC-95159, HHSN268201500003I, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
coronary artery calcium, aspirin, primary prevention, cardiovascular disease, atherosclerotic cardiovascular disease risk, bleeding risk, number needed to treat, number needed to harm, risk stratification, Pooled Cohort Equations, benefit-harm assessment, statin therapy
MeSH terms
Clinical Decision-Making, Computed Tomography Angiography, Heart Disease Risk Factors, Aged, Aged, 80 and over, Aspirin, Coronary Artery Disease, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Primary Prevention, Prospective Studies, Time Factors, United States, Incidence, Treatment Outcome, Coronary Angiography, Risk Assessment, Stroke, Vascular Calcification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review